The Entirely Subcutaneous Implantable Cardioverter-Defibrillator. Initial Clinical Experience in a Large Dutch Cohort

Objectives: The purpose of the study was to evaluate the efficacy and safety of the entirely subcutaneous implantable cardioverter-defibrillator (S-ICD). Background: A new entirely S-ICD has been introduced, that does not require lead placement in or on the heart. The authors report the largest multicenter experience to date with the S-ICD with a minimum of 1-year follow-up in the first 118 Dutch patients who were implanted with this device. Methods: Patients were selected if they had a class I or IIa indication for primary or secondary prevention of sudden cardiac death. All consecutive patie... Mehr ...

Verfasser: Olde Nordkamp, L.R.A. (Louise R.A.)
Dabiri Abkenari, L. (Lara)
Boersma, L. (Lucas)
Maass, A.H. (Alexander)
Groot, J.R. (Joris) de
Oostrom, A.J.H.H.M. van
Theuns, D.A.M.J. (Dominic)
Jordaens, L.J.L.M. (Luc)
Wilde, A.A.M. (Arthur)
Knops, R.E. (Reinoud)
Dokumenttyp: Artikel
Erscheinungsdatum: 2012
Schlagwörter: ICD / heart rhythm disturbances / implantable cardioverter-defibrillator / subcutaneous / ventricular arrhythmia
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29035604
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://repub.eur.nl/pub/37469

Objectives: The purpose of the study was to evaluate the efficacy and safety of the entirely subcutaneous implantable cardioverter-defibrillator (S-ICD). Background: A new entirely S-ICD has been introduced, that does not require lead placement in or on the heart. The authors report the largest multicenter experience to date with the S-ICD with a minimum of 1-year follow-up in the first 118 Dutch patients who were implanted with this device. Methods: Patients were selected if they had a class I or IIa indication for primary or secondary prevention of sudden cardiac death. All consecutive patients from 4 high-volume centers in the Netherlands with an S-ICD implanted between December 2008 and April 2011 were included. Results: A total of 118 patients (75% males, mean age 50 years) received the S-ICD. After 18 months of follow-up, 8 patients experienced 45